Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antihyperglycemic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually.
Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily.
Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
For patients with no history of prior antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin.
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin.
- Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily.
3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose.
To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
Patients with renal impairment
This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug must be discontinued immediately.
Improvement of glycemic control in type 2 diabetes mellitus
View approved original textHide original text
This medication helps control blood sugar levels in patients with type 2 diabetes by combining the effects of sitagliptin and metformin. It supports effective management of blood sugar levels when used in conjunction with dietary and exercise regimens, thus assisting those who struggle to control their blood sugar and improving diabetes management.
How to take
Adult dose
In antihyperglycemic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin, this drug should be taken with meals once daily, preferably in the evening, and the dose should be increased gradually.
Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily.
Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily.
1. Patients not currently receiving metformin:
For patients with no history of prior antidiabetic drug treatment who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin.
2. Patients receiving metformin:
- For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the patient's current metformin dose.
- Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin.
- Patients taking immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this drug 50/1000 mg extended-release tablets once daily.
3. Patients unable to achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione:
The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose.
To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually.
Patients with renal impairment
This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dosage adjustment.
Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months.
If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug must be discontinued immediately.
Precautions
This medication contains two active ingredients, each used for the treatment of diabetes.
First, this medication includes sitagliptin, which can rarely cause severe allergic reactions. Such reactions may include anaphylaxis, angioedema, and serious skin conditions. If any of these symptoms occur, discontinue the medication immediately and consult a healthcare professional.
Additionally, there have been reports of a serious side effect known as acute pancreatitis, characterized by inflammation of the pancreas, so patients should notify their physician immediately if they experience symptoms of pancreatitis such as abdominal pain or vomiting during treatment.
Second, the active ingredient metformin may pose risks for patients with impaired kidney function and can lead to severe metabolic abnormalities known as lactic acidosis in severe cases. Lactic acidosis can present with symptoms such as muscle pain, shortness of breath, fatigue, and abdominal pain, and immediate medical attention should be sought if these symptoms occur.
This medication should not be administered to patients with severe kidney impairment, severe infections or dehydration, acute myocardial infarction, or acute heart failure. It should also not be used by women who are pregnant or breastfeeding.
When taking this medication, it is important to be cautious about irregular eating habits, intense exercise, and interactions with certain medications, as hypoglycemia may occur, making it essential to check blood sugar levels frequently.
Furthermore, the risk may increase when this medication is taken with alcohol, so drinking should be avoided, and the medication may need to be temporarily discontinued before and after surgery.
Regular blood tests and kidney function tests should be conducted to monitor the safety of this medication, and vitamin B12 levels should also be checked periodically.
Patients should be aware of potential allergies to the pigments contained in this medication, and severe joint pain or skin conditions may arise; should these symptoms occur, medical professionals should be notified immediately.
Finally, in the event of an overdose of this medication, immediate medical treatment is necessary, and certain components can be removed via hemodialysis, so patients must adhere to medical guidance.
Side effects
Anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
lactic acidosis
hypoglycemia
diarrhea
upper respiratory tract infection
headache
nausea
Show 21 moreCollapse
vomiting
abdominal pain
nasopharyngitis
peripheral edema
hypoglycemia
severe hypoglycemia
severe and debilitating arthralgia
bullous pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
pruritus
thrombocytopenia
rhabdomyolysis
rash
urticaria
cutaneous vasculitis
increased liver enzymes
acute renal failure
constipation
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly sealed container to protect it from air and moisture. Additionally, it is recommended to keep it at room temperature between 1°C and 30°C. This will help maintain the effectiveness of the medication for a longer period.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.